Regulatory Intelligence 101 serves as an essential guide to the basics of conducting regulatory intelligence.
Regulatory intelligence (RI), the act of monitoring and analyzing available regulatory information, has become a crucial skill for regulatory professionals working in the pharmaceutical, medical device and biotechnology sectors. Regulatory Intelligence 101, new from the Regulatory Affairs Professionals Society (RAPS) serves as an essential guide to the basics of conducting regulatory intelligence.
Regulatory Intelligence 101 examines available regulatory intelligence tools, both free and those requiring a subscription, and gives tips on how to gatherinformation. Chapters cover everything from the basic regulatory intelligence toolbox to setting up a regulatory intelligence department within a company.
“This book is the culmination of my 14-year love affair with RI, a field that has allowed my affinity for regulatory and love of the profession to shine through,” writes author Meredith Brown-Tuttle, RAC, in the book’s introduction. “It reflects the contributions to the growth and development of RI through the years, and I am proud to have been part of the process.”
According to RAPS’ 2014 Scope of Practice & Compensation Report for the Regulatory Profession, regulatory intelligence currently represents an average of about 6% of regulatory professionals’ job responsibilities.
Regulatory Intelligence 101 is available from the RAPS Store for $44.95 (US) for RAPS members or $54.95 for nonmembers.
Unlock Commercial Growth through Data-Driven Patient and HCP Insights
May 2nd 2025Leveraging data-driven patient and healthcare provider (HCP) insights, including social drivers of health (SDOH), is essential for life sciences companies to continuously improve patient engagement and commercial success. Mark Rodgers, AVP of Commercial Analytics at Inovalon, discusses how identifying treatment milestones, assessing HCP performance, and segmenting patient populations using SDOH data can drive targeted strategies that improve healthcare outcomes and market access
Improving Relationships and Diversifying the Site Selection Process
April 17th 2025In this episode of the Applied Clinical Trials Podcast, Liz Beatty, co-founder and chief strategy officer, Inato, discusses a number of topics around site engagement including community-based sites, the role of technology in improving site/sponsor relationships, how increased operational costs are impacting the industry, and more.
FDA Approves Nipocalimab for the Treatment of Generalized Myasthenia Gravis
April 30th 2025Approval is based on results from the pivotal Vivacity-MG3 trial in which IMAAVY (nipocalimab-aahu) demonstrated superior disease control throughout 24 weeks when compared to placebo plus standard of care.